SCHEMBL1542849

SCHEMBL1542849

Cc1cc(C(C)(C)C)cc(-c2ccc[nH]c2=O)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
ATM Q13315 1/20 0.41
ERAP1 Q9NZ08 1/20 0.41
DAO P14920 1/20 0.40
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
PLA2G1B P04054 1/20 0.38
NFKB1 P19838 1/20 0.38
CASP3 P42574 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
TSHR P16473 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542933 0.86 AKR1C2 (0.38) NPC1RAB9AATMERAP1DAO
SCHEMBL1543435 0.86 ALDH1A1 (0.40) NPC1RAB9AATMERAP1DAO
SCHEMBL1543258 0.86 ALDH1A1 (0.38) NPC1RAB9AATMERAP1DAO
SCHEMBL1542786 0.85 NPC1 (0.39) NPC1RAB9ADAOALDH1A1L3MBTL1
SCHEMBL1542954 0.83 DAO (0.36) NPC1RAB9AATMERAP1DAO
SCHEMBL1543454 0.81 ALDH1A1 (0.46) NPC1RAB9AATMERAP1DAO
SCHEMBL18646169 0.80 CDK2 (0.35) NPC1RAB9AALDH1A1L3MBTL1PLA2G1B
SCHEMBL1543440 0.79 PTPN1 (0.38) NPC1RAB9AALDH1A1L3MBTL1PLA2G1B
SCHEMBL1542747 0.79 PARP1 (0.41) ALDH1A1TSHRCYP3A4
SCHEMBL19732817 0.77 GABRA1 (0.50) ALDH1A1GAACYP1A2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B NPC1 972/4885RAB9A 203/4885ATM 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.